Preliminary results of guanfacine treatment of acute opiate withdrawal.
Ten patients experiencing sudden opiate withdrawal received low doses of guanfacine. Improvement was noticeable within the first 4 days and was most evident in moderate to severe cases. The major effect was on autonomic symptoms. Tolerance to guanfacine was excellent.
D000208:Acute Disease; D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use*; D000328:Adult; D002986:Clinical Trials as Topic; D005260:Female; D016316:Guanfacine; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009294:Narcotics / Q000009:adverse effects*; D009293:Opioid-Related Disorders / Q000188:drug therapy; D010648:Phenylacetates / Q000627:therapeutic use*; D010865:Pilot Projects; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy*
D000316:Adrenergic alpha-Agonists; D006146:Guanidines; D009294:Narcotics; D010648:Phenylacetates; D016316:Guanfacine